A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Silence shareholders would receive cash at a 130% premium to the October 16 closing price, subject to required approvals.

Rhea-AI Summary

Silence Therapeutics (SLN) agreed to a cash acquisition by Merck KGaA, Darmstadt, Germany, valuing its equity at about $1.3 billion. The October 19 agreement offers $20.00 per American Depositary Share (ADS), a 130% premium to the October 16 close and an 82% premium to the 30-day volume-weighted average price of $10.99. Enterprise value is $1.1 billion. The U.K. scheme of arrangement is expected to close in the first quarter of 2027, subject to shareholder, court and regulatory approvals.

The deal centers on divesiran, an RNA-based therapy for polycythemia vera, a disorder involving excess red blood cells. Its Phase 2 SANRECO trial reported an 88% response rate versus 19% with placebo. Silence ADSs rose 125.58% to $19.58 on October 19. Separately, Disc Medicine (IRON) reported that its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints; its shares rose 38.86%.

4 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointMerck KGaA acquisition offers $20.00 cash per ADS, a 130% premium to Silence's October 16 close.
• Moderate pointDivesiran Phase 2 SANRECO response reached 88% versus 19% with placebo (p<0.0001).
• Minor pointDivesiran holds FDA Fast Track and Orphan Drug designations for polycythemia vera.
• Minor pointSilence ADSs rose 125.58% to $19.58 from October 16 to October 19, 2026.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Acquisition completion remains subject to shareholder, court and regulatory approvals, with closing expected in first-quarter 2027.

News Explained

Protagonist's approval-triggered payments are reported at $275 million; Keros's $20 million milestone remains expected, with 25% of net proceeds expected to go to stockholders.

The roundup reports that FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, while Keros expects a $20 million development milestone after first-patient dosing in its ELRiSE MF Phase 3 trial and expects to distribute 25% of each milestone’s net cash proceeds to stockholders.

Protagonist is also eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29%.

For Agios, the FDA decision on mitapivat’s sickle-cell application has a November 1, 2026 target date; its Phase 3 trial showed a 40.6% hemoglobin response versus 2.9% on placebo, while the pain-crisis endpoint did not reach statistical significance.

Argus 15 min delay 5 alerts

+0.58% vs previous close $79.39 last price 4.4x rel. volume Open Argus

Details

Market Reaction – IRON

-1.5% Trough in 7 min

$74.50 – $82.50 Day Range

$3.05B Mkt Cap at Last Price

On Oct 20, the day this news came out, the latest delayed price for IRON is 0.58% above the previous close. Argus tracked a trough of -1.5% from its starting point during tracking. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $79.39. Relative volume is very high at 4.4x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Trial enrollment: 183 patients Metal-free PPIX reduction: 41.4% versus placebo (p<0.0001) Increase in light without pain: 12.2 hours versus placebo (p=0.0010) +2 more

Trial enrollment

183 patients

Phase 3 APOLLO trial

Metal-free PPIX reduction

41.4% versus placebo (p<0.0001)

Whole-blood measure

Increase in light without pain

12.2 hours versus placebo (p=0.0010)

Average monthly total time in month six

NDA resubmission target

By the end of 2026

Bitopertin

Anticipated FDA decision

By mid-2027

Bitopertin

Previous Clinical trial Reports

1 past event · Latest: Mar 26

Same Type 1 event

1. Mar 26

   Phase 3 enrollment

   24h Move

   -3.1%

   Completed enrollment of 183 patients and projected APOLLO results for Q4 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

double-blind, new drug application, complete response letter

3 terms

double-blind medical

"The randomized, double-blind trial enrolled 183 patients"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

new drug application regulatory

"plans to resubmit its New Drug Application by the end of 2026"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

complete response letter regulatory

"the FDA had issued a Complete Response Letter on the earlier accelerated-approval application"

A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivotal Phase 3 trial met every primary and secondary endpoint, and its shares rose 38.86%. The same day, a developer of an RNA-based therapy for a rare blood disorder agreed to be acquired at a 130% premium, and its shares more than doubled. Several other companies working on rare blood and iron-metabolism disorders also moved higher, according to Stock Analysis data. Active Companies from around the markets with current developments this week include: Disc Medicine, Inc. (NASDAQ: IRON), Silence Therapeutics plc (NASDAQ: SLN), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Keros Therapeutics, Inc. (NASDAQ: KROS).

The common thread is the biology of red blood cells and iron. Two of these programs work through hepcidin, the hormone that controls how the body absorbs and releases iron, and others target the pathways that make heme and red blood cells. That biology sits behind conditions such as polycythemia vera, where the body overproduces red blood cells and many patients rely on repeated blood draws, and erythropoietic protoporphyria, where a buildup of protoporphyrin makes sunlight painful.

The field has been moving for months. In August, the FDA approved the first hepcidin mimetic for polycythemia vera, and two other companies in this group have FDA decisions or resubmissions on the calendar within the next year. Monday added a large acquisition and a Phase 3 readout to that list, with each company now facing its own next step.

CONTINUED... Read more market coverage at: marketupdates.com

In other industry developments and happenings in the market this week include:

Disc Medicine, Inc. (NASDAQ: IRON)

Disc Medicine announced on October 19 that its pivotal Phase 3 APOLLO trial of bitopertin in adults and adolescents with erythropoietic protoporphyria met all primary and secondary endpoints. The randomized, double-blind trial enrolled 183 patients who received 60 mg of oral bitopertin or placebo once daily for six months. Bitopertin reduced whole-blood metal-free protoporphyrin IX by 41.4% versus placebo (p<0.0001) and increased average monthly total time in light without pain in month six by 12.2 hours versus placebo (p=0.0010).

The company described bitopertin as generally well tolerated, with dizziness the most common treatment-emergent adverse event and no events above Grade 3. Disc plans to resubmit its New Drug Application by the end of 2026 and anticipates an FDA decision by mid-2027. In February, the FDA had issued a Complete Response Letter on the earlier accelerated-approval application and, according to the company, indicated that APOLLO results could serve as evidence to support traditional approval. The shares rose 38.86% on Monday to $78.93.

Silence Therapeutics plc (NASDAQ: SLN)

Silence Therapeutics agreed on October 19 to be acquired by Merck KGaA, Darmstadt, Germany, for $20.00 in cash per American Depositary Share, a 130% premium to its October 16 closing price and an 82% premium to its 30-day volume-weighted average price of $10.99. The deal carries an equity value of about $1.3 billion and an enterprise value of $1.1 billion, will be carried out through a U.K. scheme of arrangement, and is expected to close in the first quarter of 2027, subject to shareholder, court and regulatory approvals.

The deal centers on divesiran, an siRNA therapy for polycythemia vera that holds FDA Fast Track and Orphan Drug designations. In the Phase 2 SANRECO trial reported in August, 88% of patients on divesiran responded versus 19% on placebo (p<0.0001). The ADSs rose 125.58% on Monday to $19.58.

Protagonist Therapeutics, Inc. (NASDAQ: PTGX)

Protagonist's rusfertide, a hepcidin mimetic peptide, was approved by the FDA in August as MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera, the same disease divesiran targets. In the Phase 3 VERIFY trial, 76.9% of patients on MIMRYLO plus standard of care responded in Weeks 20 to 32, versus 32.9% on placebo plus standard of care. Takeda commercializes MIMRYLO, and the approval triggered $275 million in payments to Protagonist.

Protagonist is eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29%, and reported cash, cash equivalents and marketable securities of $849.5 million as of June 30, 2026. The shares rose 4.42% on Monday to $134.44.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)

Agios has the sector's next scheduled regulatory event. The FDA granted Priority Review to its supplemental application for mitapivat in sickle cell disease under the accelerated approval pathway, with a PDUFA date of November 1, 2026. In the Phase 3 RISE UP trial, 40.6% of patients on mitapivat achieved a hemoglobin response versus 2.9% on placebo, while the trial's sickle cell pain crisis endpoint did not reach statistical significance.

Mitapivat is already marketed for thalassemia as AQVESME in the U.S., where Agios reported second-quarter U.S. net revenue of $40.9 million, and the company will report third-quarter results on November 5. The shares rose 11.43% on Monday to $34.90.

Keros Therapeutics, Inc. (NASDAQ: KROS)

Keros said on September 29 that it expects a $20 million development milestone from partner Takeda following dosing of the first patient in the ELRiSE MF Phase 3 trial of elritercept in myelofibrosis patients with anemia, after an earlier $20 million milestone tied to the first patient dosed in the ELRiSE MDS Phase 3 trial. Keros expects to distribute 25% of the net cash proceeds from each milestone to stockholders.

The company reported cash and cash equivalents of $257.6 million as of June 30, 2026, which it expects to fund operations into the first half of 2028. The shares rose 3.75% on Monday to $11.06.

Biotech stocks can move 40% or more on a single readout. Learn to read the charts behind moves like these with the free Stock Preachers guide, plus The Roadmap market reports, at stockpreachers.com.

Contact Information:

marketupdates.com

Media Contact: info@marketupdates.com

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is not a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

This article is independent news commentary. Market Updates is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. MEL has not been paid by any company mentioned in this article. MEL and its owners, operators, directors, and affiliates do not currently own any shares of the companies mentioned in this article, but reserve the right to, and will, buy and sell shares of those companies at any time without further notice. Daily price changes are from the October 16, 2026 close to the October 19, 2026 close based on Stock Analysis data. Clinical results, regulatory timelines and transaction terms are as reported by the companies, remain subject to regulatory review and closing conditions, and may change. Information is drawn from company news releases and filings, published reporting and third-party data believed to be reliable, but its accuracy is not guaranteed. Investing in securities carries risk, including the loss of some or all of your investment. This document is governed by the laws of Ireland.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-phase-3-win-and-a-130-takeover-premium-lit-up-rare-blood-disease-stocks-on-monday-302913708.html

SOURCE Market Updates

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will Silence Therapeutics shareholders receive in the Merck KGaA acquisition?

The agreement provides $20.00 in cash per American Depositary Share. That represents a 130% premium to the October 16 closing price and an 82% premium to the 30-day volume-weighted average price of $10.99. The transaction values Silence's equity at about $1.3 billion and its enterprise at $1.1 billion.

When is the Silence Therapeutics acquisition expected to close?

The acquisition is expected to close in the first quarter of 2027, subject to shareholder, court and regulatory approvals. It will be carried out through a U.K. scheme of arrangement.

What FDA designations does Silence Therapeutics' divesiran hold?

Divesiran holds FDA Fast Track and Orphan Drug designations for polycythemia vera. The investigational therapy is an siRNA treatment, a type of RNA-based therapy.